STOCK TITAN

[144] IONIS PHARMACEUTICALS INC SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Ionis Pharmaceuticals, Inc. filed a Form 144 notice reporting a proposed sale of 6,849 shares of common stock, with an aggregate market value of $472,718, to be executed approximately on 10/06/2025 through Stifel Nicolaus & Company on Nasdaq. The shares were acquired as Restricted Stock Units from the issuer on 01/15/2025 and paid for in cash on the same date. The filer reports total shares outstanding of 159,391,229. The notice also lists three prior sales by the same person, Eric Swayze, totaling 38,244 shares sold on 09/02/2025, 10/01/2025, and 10/02/2025, generating combined gross proceeds of $2,346,609. The signer affirms no undisclosed material adverse information and references Rule 10b5-1 conditions.

Ionis Pharmaceuticals, Inc. ha presentato un avviso Form 144 segnalando una prevista vendita di 6,849 azioni ordinarie, con un valore di mercato complessivo di $472,718, da eseguire circa il 10/06/2025 tramite Stifel Nicolaus & Company su Nasdaq. Le azioni sono state acquisite come Restricted Stock Units dall'emittente il 01/15/2025 e pagate in contanti nello stesso giorno. Il dichiarante riporta azioni in circolazione totali di 159,391,229. L'avviso elenca anche tre vendite precedenti dallo stesso soggetto, Eric Swayze, per un totale di 38,244 azioni vendute il 09/02/2025, 10/01/2025, e 10/02/2025, generando proventi lordi combinati di $2,346,609. Il firmatario afferma che non vi sono informazioni materiale non divulgate e fa riferimento alle condizioni della Rule 10b5-1.

Ionis Pharmaceuticals, Inc. presentó un aviso Form 144 informando una venta propuesta de 6,849 acciones comunes, con un valor de mercado agregado de $472,718, para ejecutarse aproximadamente el 10/06/2025 a través de Stifel Nicolaus & Company en Nasdaq. Las acciones fueron adquiridas como Restricted Stock Units por parte del emisor el 01/15/2025 y pagadas en efectivo en la misma fecha. El presentante reporta un total de acciones en circulación de 159,391,229. El aviso también lista tres ventas previas por la misma persona, Eric Swayze, por un total de 38,244 acciones vendidas el 09/02/2025, 10/01/2025 y 10/02/2025, generando ingresos brutos combinados de $2,346,609. El firmante afirma que no existen informaciones materiales no divulgadas y hace referencia a las condiciones de la Regla 10b5-1.

Ionis Pharmaceuticals, Inc.Form 144 공시를 제출하여 6,849 주의 보통주 매각 계획을 보고했고, 총 시가가 $472,718이며, 10/06/2025경에 Nasdaq에서 Stifel Nicolaus & Company를 통해 실행될 예정입니다. 주식은 발행사로부터 Restricted Stock Units01/15/2025에 취득되었고 같은 날 현금으로 지급되었습니다. 신고인은 유통 주식 총수가 159,391,229주라고 보고합니다. 공시에는 같은 사람 Eric Swayze의 세 차례의 이전 매매도 목록에 포함되어 있으며, 총 38,244주가 09/02/2025, 10/01/2025, 10/02/2025에 매각되어 합산 총매출액은 $2,346,609입니다. 서명자는 비공개 중요 부정 정보가 없다고 확인하고 Rule 10b5-1의 조건을 참조합니다.

Ionis Pharmaceuticals, Inc. a déposé un avis Form 144 signalant une vente proposée de 6,849 actions ordinaires, pour une valeur marchande totale de $472,718, à exécuter environ le 10/06/2025 via Stifel Nicolaus & Company sur Nasdaq. Les actions ont été acquises en tant que Restricted Stock Units de l’émetteur le 01/15/2025 et payées en espèces le même jour. Le déclarant indique un total d’actions en circulation de 159,391,229. L’avis répertorie également trois ventes antérieures par la même personne, Eric Swayze, pour un total de 38,244 actions vendues le 09/02/2025, le 10/01/2025, et le 10/02/2025, générant des produits bruts cumulatifs de $2,346,609. Le signataire affirme ne disposer d’aucune information matérielle non divulguée et fait référence aux conditions de la Rule 10b5-1.

Ionis Pharmaceuticals, Inc. hat eine Form 144-Mitteilung eingereicht, in der ein geplanter Verkauf von 6,849 Stammaktien gemeldet wird, bei einem aggregierten Marktwert von $472,718, der voraussichtlich am 10/06/2025 über Stifel Nicolaus & Company an der Nasdaq durchgeführt werden soll. Die Aktien wurden als Restricted Stock Units vom Emittenten am 01/15/2025 erworben und am selben Tag in bar bezahlt. Der Einreicher meldet insgesamt ausstehende Aktien von 159,391,229. Die Mitteilung listet außerdem drei frühere Verkäufe durch dieselbe Person, Eric Swayze, insgesamt 38,244 Aktien, verkauft am 09/02/2025, 10/01/2025 und 10/02/2025, wozu sich Bruttoerlöse in Höhe von $2,346,609 ergeben. Der Unterzeichner bestätigt, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen und verweist auf die Bedingungen der Rule 10b5-1.

شركة Ionis Pharmaceuticals, Inc. قدمت إشعاراً

يذكر بيعاً مقترحاً لـ 6,849 من الأسهم العادية، بقيمة سوقية إجمالية قدرها $472,718، ليتم تنفيذه تقريباً في 10/06/2025 عبر Stifel Nicolaus & Company في Nasdaq. تم الحصول على الأسهم كـ Restricted Stock Units من الجهة المصدرة في 01/15/2025 ودفع ثمنها نقداً في نفس اليوم. يورد المقدم عدد الأسهم المعلقة الإجمالي وهو 159,391,229. كما يذكر الإشعار ثلاث مبيعات سابقة من نفس الشخص، Eric Swayze، بمجموع 38,244 سهم بيعت في 09/02/2025، 10/01/2025، و10/02/2025، محققة عوائد إجمالية مجتمعة قدرها $2,346,609. يؤكد المُوقِّع أنه لا توجد معلومات سلبية مادية غير معلنة ويشير إلى شروط القاعدة Rule 10b5-1.

Ionis Pharmaceuticals, Inc. 已提交 Form 144 通知,报告拟议出售 6,849 股普通股,市场总值为 $472,718,预计于 10/06/2025 通过 Stifel Nicolaus & CompanyNasdaq 执行。该等股票是作为发行人提供的 Restricted Stock Units01/15/2025 获得,且在同一天以现金支付。申报人报告流通中的总股本为 159,391,229 股。通知还列出同一人 Eric Swayze 的三次先前出售,总计 38,244 股,分别在 09/02/202510/01/202510/02/2025 出售,综合毛收入为 $2,346,609。签署人确认无未披露的重大负面信息,并引用 Rule 10b5-1 条件。

Positive
  • Planned sale is modest: only 6,849 shares versus 159,391,229 outstanding
  • Securities were acquired as RSUs on 01/15/2025, indicating compensation-related origin
  • Recent prior sales disclosed (total 38,244 shares), showing transparency in insider transactions
Negative
  • Concentrated recent selling: 38,244 shares sold in three transactions generating $2,346,609, which may be viewed as insider liquidity
  • No Rule 10b5-1 plan date provided in the notice, leaving uncertainty about pre-planned sale protection

Insights

TL;DR: Reported sales are routine insider liquidity from RSUs and consistent with Rule 144 disclosures.

The filing shows a planned sale of 6,849 shares (acquired as RSUs on 01/15/2025) with an aggregate market value of $472,718, through Stifel on 10/06/2025. The seller also disclosed three recent sales totaling 38,244 shares and $2,346,609 in gross proceeds across 09/02/2025, 10/01/2025, and 10/02/2025.

These items indicate insider liquidity rather than a single large block sale; compliance hinges on whether the trades follow a documented plan like Rule 10b5-1 and on the filer’s representation of no undisclosed material information. Monitor filing dates and any stated plan adoption date for clarity on pre-planned trading protection within the next weeks.

Ionis Pharmaceuticals, Inc. ha presentato un avviso Form 144 segnalando una prevista vendita di 6,849 azioni ordinarie, con un valore di mercato complessivo di $472,718, da eseguire circa il 10/06/2025 tramite Stifel Nicolaus & Company su Nasdaq. Le azioni sono state acquisite come Restricted Stock Units dall'emittente il 01/15/2025 e pagate in contanti nello stesso giorno. Il dichiarante riporta azioni in circolazione totali di 159,391,229. L'avviso elenca anche tre vendite precedenti dallo stesso soggetto, Eric Swayze, per un totale di 38,244 azioni vendute il 09/02/2025, 10/01/2025, e 10/02/2025, generando proventi lordi combinati di $2,346,609. Il firmatario afferma che non vi sono informazioni materiale non divulgate e fa riferimento alle condizioni della Rule 10b5-1.

Ionis Pharmaceuticals, Inc. presentó un aviso Form 144 informando una venta propuesta de 6,849 acciones comunes, con un valor de mercado agregado de $472,718, para ejecutarse aproximadamente el 10/06/2025 a través de Stifel Nicolaus & Company en Nasdaq. Las acciones fueron adquiridas como Restricted Stock Units por parte del emisor el 01/15/2025 y pagadas en efectivo en la misma fecha. El presentante reporta un total de acciones en circulación de 159,391,229. El aviso también lista tres ventas previas por la misma persona, Eric Swayze, por un total de 38,244 acciones vendidas el 09/02/2025, 10/01/2025 y 10/02/2025, generando ingresos brutos combinados de $2,346,609. El firmante afirma que no existen informaciones materiales no divulgadas y hace referencia a las condiciones de la Regla 10b5-1.

Ionis Pharmaceuticals, Inc.Form 144 공시를 제출하여 6,849 주의 보통주 매각 계획을 보고했고, 총 시가가 $472,718이며, 10/06/2025경에 Nasdaq에서 Stifel Nicolaus & Company를 통해 실행될 예정입니다. 주식은 발행사로부터 Restricted Stock Units01/15/2025에 취득되었고 같은 날 현금으로 지급되었습니다. 신고인은 유통 주식 총수가 159,391,229주라고 보고합니다. 공시에는 같은 사람 Eric Swayze의 세 차례의 이전 매매도 목록에 포함되어 있으며, 총 38,244주가 09/02/2025, 10/01/2025, 10/02/2025에 매각되어 합산 총매출액은 $2,346,609입니다. 서명자는 비공개 중요 부정 정보가 없다고 확인하고 Rule 10b5-1의 조건을 참조합니다.

Ionis Pharmaceuticals, Inc. a déposé un avis Form 144 signalant une vente proposée de 6,849 actions ordinaires, pour une valeur marchande totale de $472,718, à exécuter environ le 10/06/2025 via Stifel Nicolaus & Company sur Nasdaq. Les actions ont été acquises en tant que Restricted Stock Units de l’émetteur le 01/15/2025 et payées en espèces le même jour. Le déclarant indique un total d’actions en circulation de 159,391,229. L’avis répertorie également trois ventes antérieures par la même personne, Eric Swayze, pour un total de 38,244 actions vendues le 09/02/2025, le 10/01/2025, et le 10/02/2025, générant des produits bruts cumulatifs de $2,346,609. Le signataire affirme ne disposer d’aucune information matérielle non divulguée et fait référence aux conditions de la Rule 10b5-1.

Ionis Pharmaceuticals, Inc. hat eine Form 144-Mitteilung eingereicht, in der ein geplanter Verkauf von 6,849 Stammaktien gemeldet wird, bei einem aggregierten Marktwert von $472,718, der voraussichtlich am 10/06/2025 über Stifel Nicolaus & Company an der Nasdaq durchgeführt werden soll. Die Aktien wurden als Restricted Stock Units vom Emittenten am 01/15/2025 erworben und am selben Tag in bar bezahlt. Der Einreicher meldet insgesamt ausstehende Aktien von 159,391,229. Die Mitteilung listet außerdem drei frühere Verkäufe durch dieselbe Person, Eric Swayze, insgesamt 38,244 Aktien, verkauft am 09/02/2025, 10/01/2025 und 10/02/2025, wozu sich Bruttoerlöse in Höhe von $2,346,609 ergeben. Der Unterzeichner bestätigt, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen und verweist auf die Bedingungen der Rule 10b5-1.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Ionis (IONS) report in this Form 144?

The filing reports a proposed sale of 6,849 shares of common stock (aggregate market value $472,718) to be sold around 10/06/2025 via Stifel Nicolaus on Nasdaq.

How were the shares acquired that are being sold?

The shares were acquired as Restricted Stock Units on 01/15/2025 and the purchase was paid in cash on that date.

Who recently sold shares for the account referenced in the filing?

Eric Swayze sold 11,130, 14,142, and 12,972 shares on 09/02/2025, 10/01/2025, and 10/02/2025, respectively, totaling 38,244 shares and $2,346,609 in gross proceeds.

What fraction of Ionis shares does the proposed sale represent?

The proposed sale of 6,849 shares is a small fraction of the reported 159,391,229 shares outstanding.

Does the filing indicate a Rule 10b5-1 trading plan date?

No specific plan adoption date is provided in the notice; the filer references Rule 10b5-1 conditions but did not state a plan date.
Ionis Pharmaceuticals

NASDAQ:IONS

IONS Rankings

IONS Latest News

IONS Latest SEC Filings

IONS Stock Data

11.00B
158.14M
0.65%
108.48%
6.59%
Biotechnology
Pharmaceutical Preparations
Link
United States
CARLSBAD